P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab

Figures & data

Figure 1 Mechanism of action of crizanlizumab. Crizanlizumab is a monoclonal antibody that binds to P-selectin. Blockade of P-selectin may prevent cell–cell interactions between blood cells and endothelial cells, and thus eliminate or reduce vaso-occlusion. Figure reproduced with permission from© 2020 Novartis AG.

Abbreviations: GP1bα, glycoprotein 1bα; PSGL-1, P-selectin glycoprotein ligand-1.

Figure 2 SCPC event-free patients in the high-dose crizanlizumab, low-dose crizanlizumab, and placebo subgroups in an ITT population with respect to the annualized crisis rate in the preceding year.

Note: Data from Kutlar et al.³⁴

Abbreviations: SCPC, sickle cell pain crisis; ITT, intention to treat.

Kutlar A, Kanter J, Liles D, et al. Crizanlizumab, a P-selectin inhibitor, increases the likelihood of experiencing a sickle cell-related pain crisis while on treatment: results from Phase II SUSTAIN study. In:European Hematology Association abstract [Internet]. European Hematology Association library; 2017. Available from: https://library.ehaweb.org/eha/2017/22nd/181741/abdullah.kutlar.crizanlizumab.a.p-selectin.inhibitor.increases.the.likelihood.html?f=m3s619830e1181.

 Google Scholar